摘要
目的探讨Luminal A型乳腺癌术后辅助化疗临床疗效。方法 47例Luminal A型乳腺癌患者分为2组:化疗联合内分泌治疗组采取乳腺癌术后辅助常规CEF化疗方案、化疗结束后序贯内分泌治疗。内分泌治疗组,口服三苯氧胺或者芳香化酶抑制剂。评价各组1年无病生存期(DFS),2年DFS和不良反应。结果内分泌组1年、2年的DFS均高于化疗联合内分泌治疗组,且不良反应轻微。结论 Luminal A型乳腺癌患者术后内分泌辅助治疗效果良好。
Objective To investigate the clinical efficacy of postoperative adjuvant chemotherapy for Luminal A type of breast cancer.Methods Forty-seven Luminal A type of breast cancer were randomly divided into two groups.Chemotherapy combined with endocrine group took conventional CEF chemotherapy adjuvant breast cancer and sequential endocrine therapy after chemotherapy.Endocrine group orally took Tamoxifen or Aromatase inhibitors.The 1-year DFS,2-year DFS and adverse reactions of the two groups were evaluated.Results 1,2-year DFS of the endocrine group was higher than the chemotherapy combined with endocrine treatment group,and adverse reactions were mild.Conclusion The clinical effect of endocrine adjuvant treatment in Luminal A type breast cancer is obviously positive.
出处
《实用临床医药杂志》
CAS
2011年第17期159-160,164,共3页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金资助项目(41120003)
